Mar. 3, 2025 — Psoriasis is one of the most common chronic inflammatory skin diseases, affecting around 250,000 people in Austria. While previous treatment approaches have mainly focused on ...

Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents ...

The psoriasis pipeline possesses some drugs in mid- and late-stage development to be approved in the near future. The emerging landscape holds a diverse range of therapeutic alternatives for treatment ...

Stress, infections, and corticosteroid withdrawal are known triggers of generalized pustular psoriasis (GPP). However, doctors cannot attribute every GPP flare to a specific cause. Psoriasis is an ...

Icotrokinra had more significant improvements than placebo for multiple skin clearance measures following 16 weeks of treatment for plaque psoriasis in adolescents and adults. Icotrokinra is ...

Many people who have psoriasis will experience the telltale sign of itchiness or burning. But for people with differing skin tones, that’s where the similarities may end. The symptoms of ...

Please provide your email address to receive an email when new articles are posted on . The mean annualized flare rate per patient per year was 0.91, with a mean time of 5.9 months between flares.

Obesity was linked to reduced long-term effectiveness of biologic therapy in patients with severe plaque psoriasis in a study, with dysregulated innate immune responses contributing to treatment ...

In your practice, what are the rates of persistence and adherence to plaque psoriasis treatment, and what key factors influence these outcomes?

Psoriatic arthritis (PsA) is a chronic (long-lasting) condition that combines the skin-related symptoms of psoriasis with the joint-related symptoms of arthritis. PsA is an autoimmune disease ...

Jason Roth "Psoriasis is something I lived with quietly for many years. It was part of my life even during my most public moments, including on tours, but I rarely, if ever, spoke about it ...

Improved targeting of the molecular drivers of psoriasis has paved the way for new oral therapies that offer the potential for major responses in a majority of patients. Identification of better ...